Trial Profile
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Lomustine
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 18 Oct 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 17 Aug 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.
- 18 Aug 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.